RenovoRx, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNXT Nasdaq 2836 renovorx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RenovoRx, Inc.

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Jan 8th, 2026 6:30 am
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - Dec 11th, 2025 6:30 am
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Dec 8th, 2025 7:00 am
High Growth US Tech Stocks To Watch In December 2025 - Dec 4th, 2025 10:38 am
US High Growth Tech Stocks to Watch - Dec 4th, 2025 4:38 am
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Dec 1st, 2025 7:00 am
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Dec 1st, 2025 6:30 am
US High Growth Tech Stocks To Watch November 2025 - Nov 21st, 2025 4:38 am
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - Nov 19th, 2025 6:30 am
RenovoRx Inc (RNXT) Q3 2025 Earnings Call Highlights: Strong Commercial Momentum and Strategic ... - Nov 13th, 2025 10:04 pm
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - Nov 13th, 2025 3:30 pm
RenovoRx (RNXT) Q3 2025 Earnings Call Transcript - Nov 13th, 2025 3:25 pm
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update - Nov 13th, 2025 2:05 pm
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD - Nov 6th, 2025 6:30 am
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th - Nov 4th, 2025 6:30 am
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - Oct 27th, 2025 6:30 am
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD - Oct 9th, 2025 6:30 am
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites - Sep 25th, 2025 6:30 am
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025 - Sep 16th, 2025 6:00 am
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th - Sep 11th, 2025 6:30 am